Lancet Oncology Mds Myelodysplastic Syndromes
The Myelodysplastic Syndromes Foundation says data published in the peer reviewed medical journal The Lancet Oncology confirms Vidaza extends survival for patients with higher-risk MDS.
Webcastr | February 18, 2009
Tags:. .myelodysplastic. .mds. .syndromes. .lancet oncology